Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Potassium chloride
Essential Pharma (M) Limited
A12BA; A12BA01
Potassium chloride
600 milligram(s)
Prolonged-release tablet
Potassium; potassium chloride
Not marketed
2016-05-26
Slo600mgTab-LPL-IE-4 1/7 Package Leaflet: information for the user SLOW-K ® 600 MG PROLONGED-RELEASE COATED TABLETS POTASSIUM CHLORIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET 1. What Slow-K is and what it is used for 2. Before you take Slow-K 3. How to take Slow-K 4. Possible side effects 5. How to store Slow-K 6. Further information 1 WHAT SLOW-K IS AND WHAT IT IS USED FOR The name of your medicine is Slow-K 600mg Prolonged-release Coated Tablets (called Slow-K in this leaflet). It contains a medicine called potassium chloride. It has a special slow-release system that releases your medicine evenly throughout the day. Slow-K is used to treat or prevent low levels of potassium in your body. This might be because: you have sickness or diarrhoea you are using certain medicines you have a kidney or gut problem you have certain metabolic diseases you do not get enough potassium from your normal diet you have an illness that runs in your family (genetic disease) Slow-K is usually used in people who cannot take potassium chloride as a liquid or tablet that dissolves. Slo600mgTab-LPL-IE-4 2/7 2 BEFORE YOU TAKE SLOW K DO NOT TAKE SLOW-K IF: you are allergic to potassium chloride or any of the other ingredients of this medicine (listed in Section 6) you have kidney failure you have severe or long-lasting diarrhoea you have untreated Addison’s Syndrome (underactive adrenal glands) you have a hormone problem called “hypo-aldosteronism” any part of your food pipe, stomach or gut has a narrowing in it (called a “strict Read the complete document
Health Products Regulatory Authority 13 November 2020 CRN00C15N Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Slow K 600mg Prolonged-release Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One sugar-coated tablet contains 600 mg potassium chloride as active substance equivalent to 8 mmol potassium ion (K+). Excipients: Each tablet contains 96.4mg sucrose. For a full list of excipients, see section 6.1, list of excipients. 3 PHARMACEUTICAL FORM Coated tablet Pale orange, round, biconvex, polished sugar-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use in patients requiring supplemental potassium therapy. Uses include: Supplement to potassium depleting diuretics. Hypokalaemia associated with prolonged corticosteroid therapy. Where there is inadequate dietary intake due to poor dietary habits or malnutrition. Increased gastrointestinal potassium loss due for example to vomiting (except pyloric stenosis) or diarrhoea. Increased renal potassium loss in primary or secondary hyperaldosteronism, Cushing's syndrome and renal tubular disease. Altered transcellular shifts of potassium as in hypokalaemic familial periodic paralysis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is important that the tablets should be swallowed whole, with fluid during meals, whilst the patient is sitting upright. _GENERAL POPULATIONS:_ The dosage of Slow-K should be adjusted to the individual needs of each patient. 2-3 tablets daily are usually an adequate supplement to prevent hypokalaemia. In states of potassium deficiency doses of 5 to 6 tablets daily may be needed increasing up to 12 tablets daily in severe deficiency. If the dosage exceeds 16mmol K+ (2 tablets) it should be taken in divided doses. Where intermittent diuretic therapy is being used, it is advisable to give Slow K on intervening days between administration of the diuretic. The response to treatment should preferably be monitored by repeat determination of plasma potassium and Slow K continued until the hypo Read the complete document